Helix BioPharma Corp. presented new data on its CEACAM6-directed antibody-drug conjugate program at the 16th Annual World ADC London conference. The presentation, delivered by Jonathan Davis, PhD, Director of ADC Discovery at Helix BioPharma, focused on next-generation ADCs designed to unlock the potential of CEACAM6-directed targeted therapies.
The conference, now in its 16th year, is the longest-standing global event dedicated to ADC research and development, bringing together more than 700 industry stakeholders from over 240 companies. Dr. Davis was selected to present as part of the conference's Seminar Day program, which addresses key challenges and opportunities in next-generation conjugate design, safety, combination strategies, and regulatory development.
The presentation highlighted CEACAM6 as a highly attractive therapeutic target due to its elevated expression across a broad range of epithelial cancers, its association with poor clinical outcomes, and its limited expression in healthy tissues. Dr. Davis presented data supporting the tumor-selective binding profile of Helix's proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibodies that demonstrated preferential binding to tumor-expressed CEACAM6.
This selective binding profile supports the development of next-generation ADCs designed to deliver potent therapeutic payloads directly to cancer cells while minimizing off-target effects. The approach builds on the clinical foundation set by Tumor Defense Breaker L-DOS47, Helix's lead CEACAM6-targeted candidate, which has demonstrated favorable safety and encouraging clinical activity in Phase I/II studies in non-small cell lung cancer.
"CEACAM6 represents a compelling and underexploited target with broad potential across multiple hard-to-treat cancers," said Dr. Davis. "Our proprietary VHH-based targeting approach enables highly selective tumor binding, supporting the development of next-generation ADCs designed to maximize therapeutic impact while minimizing off-target effects."
The presentation generated strong interest and discussion among conference participants, reflecting growing recognition of CEACAM6 as an important emerging target in oncology. A copy of the presentation is available on the company's website at https://helixbiopharma.com/wp-content/uploads/2026/02/Unlocking-the-Potential-of-CEACAM6.pdf.
For business and technology leaders in the oncology space, this development signals continued innovation in targeted cancer therapies. The CEACAM6 target's broad applicability across epithelial cancers suggests potential for addressing multiple cancer types with a single therapeutic approach. The proprietary VHH technology represents a technological advancement in antibody design that could improve therapeutic precision and reduce side effects compared to traditional antibody approaches.
The World ADC London conference continues with a comprehensive scientific program covering advances in ADC discovery, development, and clinical translation. More information about the conference is available at https://worldadc-europe.com/.
